Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15793MR)

This product GTTS-WQ15793MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15793MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14127MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ9624MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ13232MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ13318MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ3270MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ7941MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ7015MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ1444MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW